Jenni Kauppi

Dr. Jenni Kauppi

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2023 in BMJ Open
Verified
Journal Article
Open access
PDF file
JTJanis Timsans
Janis Timsans
JKJenni Kauppi
Jenni Kauppi
AKAnne Kerola
Anne Kerola
TLTiina Maarit Lehto
Tiina Maarit Lehto
HKHannu Kautiainen
Hannu Kautiainen
MKMarkku Jaakko Kauppi
Markku Jaakko Kauppi
Objective To establish the prevalence of hyperuricaemia in an elderly Finnish cohort and to assess its association with comorbidities and mortality. Design Prospective cohort study. Setting Good Ageing in Lahti Region study, Finland 2002–2012 (mortality data analysed until 2018). Participants 2673 participants (mean age 64 years; 47% men). Primary and secondary outcome measures Prevalence of hyperuricaemia in the study population was detected. Associations between hyperuricaemia and mortality were assessed using multivariable adjusted Cox proportional hazards models. Methods Data from a prospective, population-based study of elderly people (52–76 years) in the Lahti region, Finland, were used. Information on serum uric acid (SUA) levels as well as several other laboratory variables, comorbidities, lifestyle habits and socioeconomic factors was collected, and the association between SUA level and mortality in a 15-year follow-up period was analysed. Results Of 2673 elderly Finnish persons included in the study 1197 (48%) were hyperuricaemic. Hyperuricaemia was extremely prevalent in men (60%). There was an association between elevated SUA and mortality which remained after adjustment for potential confounding factors (age, gender, education, smoking status, body mass index, hypertension and dyslipidaemia). The adjusted HR for all-cause mortality among clearly hyperuricaemic individuals with SUA≥420 µmol/L compared with normouricaemic individuals (SUA<360 µmol/L) was 1.32 (95% CI 1.05 to 1.60) in women and 1.29 (95% CI 1.05 to 1.60) in men. In slightly hyperuricaemic individuals (SUA 360–420 µmol/L) the corresponding HRs were 1.03 (95% CI 0.78 to 1.35) and 1.11 (95% CI 0.89 to 1.39). Conclusions Hyperuricaemia is very prevalent in the elderly Finnish population and is independently associated with increased mortality.

17 October 2023 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
JTJanis Timsans
Janis Timsans
JKJenni Kauppi
Jenni Kauppi
AKAnne Kerola
Anne Kerola
TLTiina Maarit Lehto
Tiina Maarit Lehto
HKHannu Juhani Kautiainen
Hannu Juhani Kautiainen
MKMarkku Jaakko Kauppi
Markku Jaakko Kauppi

11 April 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JTJanis Timsans
Janis Timsans
JKJenni Kauppi
Jenni Kauppi
VRVappu Rantalaiho
Vappu Rantalaiho
AKAnne Kerola
Anne Kerola
KHKia Hakkarainen
Kia Hakkarainen
MKMarkku Jaakko Kauppi
Markku Jaakko Kauppi
Background: Glucose metabolism disorders are major contributors to morbidity and mortality. Elevated serum uric acid (SUA) is closely linked to the cardiometabolic consequences of glucose metabolism disorders, various other comorbidities, and mortality. In this study, we explore the relationship between SUA and fasting plasma glucose (FPG), insulin levels, and insulin resistance in an older Finnish adult cohort. Methods: We used data from the GOAL (GOod Ageing in Lahti region) study—a prospective, population-based study of Finnish individuals aged 52–76 years. A total of 2322 non-diabetic subjects were included in the study. Data of SUA, FPG, and other laboratory parameters, comorbidities, lifestyle habits, and socioeconomic factors were collected. Subjects with SUA values of >410 μmol/L (≈6.9 mg/dL; 75th percentile) were regarded as hyperuricemic. We investigated the relationship between SUA and FPG, insulin levels, and insulin resistance [homeostatic model assessment of insulin resistance (HOMA-IR) ≥2.65]. Results: We found statistically significant sex-, age- and BMI-adjusted small to moderate relationships (Cohen’s standard for β values above 0.10 and 0.30, respectively) between SUA and FPG, insulin levels, and insulin resistance in the whole study population as well as in the female and male subgroups. The higher the SUA level, the higher the HOMA-IR [(adjusted β = 0.21 (95% CI: 0.17 to 0.25)], and it rises drastically if SUA is above 400 μmol/L (≈6.7 mg/dL). The probability of a subject having insulin resistance is related to SUA level. Conclusions: Hyperuricemia is associated with elevated FPG and insulin resistance, emphasizing the importance of addressing both conditions. Further research may explore hyperuricemia treatment’s role in preventing glucose metabolism disorders and their cardiometabolic consequences.

28 May 2025 in Metabolites
Verified
Journal Article
Open access
PDF file
JTJanis Timsans
Janis Timsans
JKJenni Kauppi
Jenni Kauppi
VRVappu Rantalaiho
Vappu Rantalaiho
AKAnne Kerola
Anne Kerola
KHKia Hakkarainen
Kia Hakkarainen
MKMarkku Jaakko Kauppi
Markku Jaakko Kauppi
Background: Hyperuricemia and steatotic liver disease are both associated with various comorbidities and mortality. This study was carried out to study the association between hyperuricemia and steatotic liver disease and to assess the impact of the etiology of hyperuricemia on the development of steatotic liver disease. Methods: Data from a population-based study of 2635 individuals aged 52–76 years was used. Hyperuricemia was defined as a serum urate (SU) of >410 μmol/L (≈6.9 mg/dL; 75th percentile) and steatotic liver disease as a fatty liver index (FLI) of ≥80 (75th percentile). We defined hyperuricemia as renal if estimated glomerular filtration rate (eGFR) was ≤67 mL/min/1.73 m2 (25th percentile) and as metabolic if eGFR was >67 mL/min/1.73 m2. Results: FLI correlated with SU in women [r = 0.47 (95% CI: 0.43 to 0.51)] and men [r = 0.37 (95% CI: 0.32 to 0.42)]. Compared to those with SU ≤ 410 μmol/L and FLI < 80, the hazard ratio (HR) for all-cause mortality was 1.76 (95% CI: 1.39 to 2.23) in hyperuricemic individuals with FLI ≥ 80, 1.16 (95% CI: 0.95 to 1.40) in hyperuricemic individuals with FLI < 80, and 1.34 (95% CI: 1.06 to 1.70) in persons with SU ≤ 410 μmol/L and FLI ≥ 80. Individuals with metabolic hyperuricemia had a statistically significantly higher FLI than individuals with renal hyperuricemia: mean (SD) = 73.4 (12.2) and 69.6 (22.5), respectively, p = 0.015 after adjusting for sex and diabetes. Conclusions: FLI correlates positively with SU, and it is higher in persons with metabolic hyperuricemia. Both steatotic liver disease and hyperuricemia increase mortality.